White House announces a most-favored-nation deal with Regeneron

The White House confirmed that Regeneron has joined the Most-Favored-Nation (MFN) pricing program, becoming one of the manufacturers now tied to TrumpRx.gov, the federal website launched to sell brand-name drugs at prices closer to what other wealthy countries pay ^[1]. A fact sheet dated April 23, 2026, is titled "Deal with Regeneron to Bring Most-Favored-Nation Pricing to American Patients," though the detailed terms of that specific agreement, including which Regeneron products are covered and at what price, are not included in the materials reviewed for this story ^[1].

What is known is the broader shape of the MFN program. When TrumpRx.gov launched on February 5, 2026, it featured drugs from five manufacturers that had already struck MFN deals: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer ^[1]. At that time, the administration said it had reached 16 total MFN deals with manufacturers since September 30, 2025, with more products expected to appear on the site "in the coming months" ^[1]. Regeneron's addition fits that pattern of a rolling expansion rather than a one-time event.

For readers of this site, the most directly relevant numbers from the February launch involve semaglutide and tirzepatide products already covered under earlier deals. The administration said the monthly price of Ozempic would fall from $1,028 to an average of $350, and as low as $199 depending on dosage strength ^[1]. Injectable Wegovy was set to drop from $1,349 to the same average and floor prices, while the oral Wegovy pill was listed as falling to as low as $149 ^[1]. Zepbound, Eli Lilly's tirzepatide product, was slated to fall from $1,088 to an average of $346 and as low as $299 depending on dose ^[1]. These figures came from the original five-manufacturer rollout and are not new as of the Regeneron announcement ^[1].

Regeneron is not a maker of GLP-1 obesity or diabetes drugs; its major products include treatments for eye disease and skin conditions, though the sources here do not specify which of its drugs, if any, are covered by this MFN deal ^[1]. Because the fact sheet text for the Regeneron-specific agreement was not part of the material reviewed, it is not yet known whether this deal touches any GLP-1 medicines at all.

Why it matters for patients

For people taking or considering semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide (Mounjaro, Zepbound), the Regeneron deal itself likely has no direct bearing on their prescriptions, since Regeneron's core business does not overlap with GLP-1 drugs based on what is confirmed here ^[1]. The relevant pricing changes for GLP-1 users came from the earlier deals with Novo Nordisk and Eli Lilly, which set the $350 average Ozempic price and the $346 average Zepbound price cited in the February fact sheet ^[1]. What the Regeneron news does show is that the MFN program keeps growing, and patients on any brand-name drug should watch TrumpRx.gov for updates, since the administration has said more manufacturers' products will be added over time ^[1].

What happens next

The White House said additional drugs from manufacturers with signed MFN deals would appear on TrumpRx.gov "in the coming months" after the February 5, 2026 launch ^[1]. A separate fact sheet on expanding TrumpRx.gov was dated May 18, 2026, and another announcing deals with nine more manufacturers was dated August 31, 2026, suggesting the rollout continued well past the Regeneron announcement, though details of those later additions are not part of the sources reviewed here ^[1].